Subject characteristics
| Chlamydia pneumoniae antibody titre | p-value | ||
| Raised | Not raised | ||
| Subjects | 20 (38) | 33 (63) | NA |
| Male sex | 8 (24) | 6 (30) | 0.6 |
| Age yrs# | 47.6±3.2 | 43.3±2.8 | 0.4 |
| Current smoker | 3 (15) | 4 (12) | 0.5 |
| Atopy | 14 (70) | 18 (55) | 0.3 |
| Background Aas score¶ | 4.0±1.8 | 4.0±1.5 | 0.6 |
| ICS dose at presentation+ µg BDP·day−1 | 1618±208 | 1625±154 | 0.6 |
| Acute FEV1 % pred | 69.3±9.4 | 64±6.8 | 0.7 |
| Admitted | 12 (60) | 21 (64) | 0.8 |
| Length of stay days§ | 2 (0–8) | 1 (0–9) | 0.9 |
| FEV1 at follow-up % pred | 71.2±5.0 | 75.4±5.0 | 0.6 |
| PD20 at follow-up mL·min−1 | 4.7±1.4 | 4.2±1.3 | 0.8 |
| Taking prednisoneƒ | 8 (44) | 12 (40) | 0.8 |
Data are presented as n (%) or mean±sem unless otherwise indicated
NA: not applicable
ICS: inhaled corticasteroid
BDP: beclomethasone dipropionate
FEV1: forced expiratory volume in one second
% pred: percentage of the predicted value
PD20: provocative dose of saline causing a 20% fall in FEV1
#: mean±sd
¶: provides measure of asthma severity 9
+: BDP≡1 µg budesonide≡0.5 µg fluticasone propionate
§: median (interquartile range)
ƒ: commenced before presentation